Adicet Bio, Inc. (ACET)
| Market Cap | 451.32M |
| Revenue (ttm) | 9.67M |
| Net Income (ttm) | -55.14M |
| Shares Out | 39.14M |
| EPS (ttm) | -2.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 117,172 |
| Open | 12.12 |
| Previous Close | 11.95 |
| Day's Range | 11.45 - 12.52 |
| 52-Week Range | 6.25 - 18.49 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 30.86 (+167.6%) |
| Earnings Date | n/a |
About ACET
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase 1 clinical study for the treatment of non-Hodgkin's lymphoma. The company a...
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for Adicet Bio stock is "Strong Buy." The 12-month stock price forecast is 30.86, which is an increase of 167.65% from the latest price.
News
3 Biotech Stocks That Could Double in 2022
They're risky. But with the high risk comes the potential for high rewards.
Adicet Bio, Inc. Announces Closing of $100 Million Public Follow-On Offering and Exercise in Full of the Underwriters...
MENLO PARK, Calif. and BOSTON, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapie...
Adicet Bio Raises $87M Via Equity To Fund Development Of Non-Hodgkin's Lymphoma Candidate
Adicet Bio Inc (NASDAQ: ACET) priced an underwritten public offering of 6.25 million shares at $14.00 per share, raising gross proceeds of $87.5 million. The offer price represents a discount of almost ...
Adicet Bio, Inc. Announces Pricing of Public Offering of Common Stock
MENLO PARK, Calif. and BOSTON, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapie...
Adicet Bio, Inc. Announces Proposed Follow-On Offering of Common Stock
MENLO PARK, Calif. and BOSTON, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapie...
Why Adicet Bio Stock Is Skyrocketing Today
The company reported positive interim results from a phase 1 study.
Adicet Stock Rallies After Early Responses For Off-The-Shelf Drug In B-cell Non-Hodgkin's Lymphoma
Adicet Bio Inc (NASDAQ: ACET) has announced positive interim data from its dose-escalation Phase 1 study evaluating ADI-001 for B-cell Non-Hodgkin's Lymphoma. Adicet's AD-001 is an off-the-shelf cell t...
Adicet Bio Announces Positive Interim Clinical Data From First-Ever Allogeneic, Off-The-Shelf, Gamma Delta CAR T Inve...
MENLO PARK, Calif. and BOSTON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta CAR T cell ther...
Adicet Bio to Host Webcast Presentation of ADI-001 Interim Clinical Data in B Cell Non-Hodgkin's Lymphoma
ADI-001 is the first ever allogeneic, off-the-shelf, gamma delta CAR T cell therapy to report clinical data
Adicet Announces Appointment of Dr. Michael G. Kauffman to the Board of Directors
MENLO PARK, Calif. and BOSTON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapie...
Adicet Presents Preclinical Data for ADI-002, a GPC3-Targeted Development Candidate for Solid Tumors, at the SITC Ann...
Adicet's allogeneic gamma delta CAR-T cell therapy candidate is designed to combine CAR targeting and cell intrinsic IL-15 armoring with the innate and adaptive immune effector functions of the Company'...
Adicet Bio, Inc. (ACET) Reports Q3 Loss, Lags Revenue Estimates
Adicet Bio, Inc. (ACET) delivered earnings and revenue surprises of -15.79% and -26.26%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Adicet Reports Third Quarter 2021 Financial Results and Provides Business Updates
MENLO PARK, Calif. and BOSTON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapie...
Adicet Bio to Participate in Stifel 2021 Virtual Healthcare Conference
MENLO PARK, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cance...
Adicet Announces Trials in Progress Poster Presentation for ADI-001 at 2021 ASH Annual Meeting
MENLO PARK, Calif. and BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapie...
CDR-Life Announces Expansion of Scientific Advisory Board
Two renowned experts join to advise CDR-Life as the company advances pipeline of novel cancer therapeutic candidates Two renowned experts join to advise CDR-Life as the company advances pipeline of nove...
Adicet Announces Promotion of Blake Aftab, Ph.D. to Chief Scientific Officer
MENLO PARK, Calif. and BOSTON, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapie...
Adicet to Present Preclinical Data from Allogeneic Gamma Delta T Cell Platform at SITC 36th Annual Meeting
MENLO PARK, Calif. and BOSTON, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapie...
Twist Bioscience Collaborates with Adicet Bio to Accelerate Discovery of Gamma Delta T Cell Cancer Therapeutics
SOUTH SAN FRANCISCO, Calif. & MENLO PARK, Calif. & BOSTON--(BUSINESS WIRE)--Twist Bioscience and Adicet Bio collaboration to accelerate the discovery of gamma delta T cell therapies against five undiscl...
Adicet Bio to Participate in Upcoming Investor Conferences
MENLO PARK, Calif. and BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer a...
Adicet Bio, Inc. (ACET) Reports Q2 Loss, Tops Revenue Estimates
Adicet Bio, Inc. (ACET) delivered earnings and revenue surprises of 33.33% and 6.96%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Adicet Reports Second Quarter 2021 Financial Results and Provides Business Updates
On track to report top-line interim data from ADI-001 Phase 1 study in Non-Hodgkin's Lymphoma (NHL) by the end of 2021 On track to report top-line interim data from ADI-001 Phase 1 study in Non-Hodgkin'...
Adicet Bio Announces Formation of Scientific Advisory Board
MENLO PARK, Calif and BOSTON, July 15, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and...
Adicet Bio Added to the Russell 2000® Index
MENLO PARK, Calif. and BOSTON, June 28, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer an...
Moving Average Crossover Alert: Adicet Bio (ACET)
Adicet Bio (ACET) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.